Forensics

DNA analysis company awarded FBI contracts to develop SNP technology

Published in Medical Letter on the CDC and FDA, December 28th, 2003

Orchid BioSciences, Inc., (ORCH) announced that its Orchid Cellmark unit was awarded two contracts from the U.S. Federal Bureau of Investigation to develop specific aspects of the company's SNP (single nucleotide polymorphism) technology for additional forensic DNA testing applications.

The goal of the two contracts is to develop new forensic tools that will increase the ability of investigators to identify individuals using DNA samples that have degraded and therefore contain a limited amount of genetic material. Work on both of these contracts is being undertaken in Orchid Cellmark's Dallas, Texas, facility and is expected to be completed in about 1 year.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2003-12-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry